BRPI0818272A2 - Antígeno associado com artrite reumatóide - Google Patents

Antígeno associado com artrite reumatóide

Info

Publication number
BRPI0818272A2
BRPI0818272A2 BRPI0818272-8A BRPI0818272A BRPI0818272A2 BR PI0818272 A2 BRPI0818272 A2 BR PI0818272A2 BR PI0818272 A BRPI0818272 A BR PI0818272A BR PI0818272 A2 BRPI0818272 A2 BR PI0818272A2
Authority
BR
Brazil
Prior art keywords
rheumatoid arthritis
antigen associated
antigen
rheumatoid
arthritis
Prior art date
Application number
BRPI0818272-8A
Other languages
English (en)
Inventor
Manuela Kaspar
Kathrin Schwager
Eveline Trachsel
Original Assignee
Philogen Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philogen Spa filed Critical Philogen Spa
Publication of BRPI0818272A2 publication Critical patent/BRPI0818272A2/pt
Publication of BRPI0818272B1 publication Critical patent/BRPI0818272B1/pt
Publication of BRPI0818272B8 publication Critical patent/BRPI0818272B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
BRPI0818272A 2007-10-30 2008-10-27 uso de um membro de ligação que se liga à isoforma extra domínio-a (ed-a) da fibronectina para a preparação de um medicamento para tratamento de artrite reumatóide BRPI0818272B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98360607P 2007-10-30 2007-10-30
US60/983,606 2007-10-30
PCT/EP2008/009070 WO2009056268A1 (en) 2007-10-30 2008-10-27 An antigen associated with rheumatoid arthritis

Publications (3)

Publication Number Publication Date
BRPI0818272A2 true BRPI0818272A2 (pt) 2015-04-14
BRPI0818272B1 BRPI0818272B1 (pt) 2021-01-12
BRPI0818272B8 BRPI0818272B8 (pt) 2021-05-25

Family

ID=40282320

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818272A BRPI0818272B8 (pt) 2007-10-30 2008-10-27 uso de um membro de ligação que se liga à isoforma extra domínio-a (ed-a) da fibronectina para a preparação de um medicamento para tratamento de artrite reumatóide

Country Status (18)

Country Link
US (4) US8222377B2 (pt)
EP (3) EP3783019A1 (pt)
JP (3) JP5106635B2 (pt)
KR (3) KR102002739B1 (pt)
CN (2) CN103396483B (pt)
AU (1) AU2008317941B2 (pt)
BR (1) BRPI0818272B8 (pt)
CA (1) CA2704296C (pt)
DK (2) DK2209805T3 (pt)
ES (2) ES2646228T3 (pt)
HU (2) HUE037036T2 (pt)
MX (1) MX2010004726A (pt)
NO (1) NO2209805T3 (pt)
PL (2) PL3281952T3 (pt)
PT (2) PT3281952T (pt)
RU (2) RU2486198C2 (pt)
SI (2) SI3281952T1 (pt)
WO (1) WO2009056268A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070084556A1 (en) 2005-10-14 2007-04-19 Langseder Neal E Method of applying a label to a squeeze tube
AU2008234615B2 (en) * 2007-04-02 2013-10-10 Philogen S.P.A. The ED-A antigen of fibrinogen is associated with the neovasculature of tumour metastases
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
EP3783019A1 (en) 2007-10-30 2021-02-24 Philogen S.p.A. An antigen associated with rheumatoid arthritis
WO2010078950A2 (en) * 2009-01-07 2010-07-15 Philogen S.P.A. Antigens associated with endometriosis, psoriatic arthritis and psoriasis
CA2769882C (en) 2009-08-05 2016-10-11 Philogen S.P.A. Targeting of bone marrow neovasculature
CA2842053C (en) * 2011-07-27 2018-01-16 Philogen S.P.A. Il-12 immunoconjugate
WO2014023673A1 (en) * 2012-08-08 2014-02-13 Roche Glycart Ag Interleukin-10 fusion proteins and uses thereof
TWI499426B (zh) * 2012-09-27 2015-09-11 Philogen Spa 與發炎性腸病有關之抗原
EP2903629B1 (en) * 2012-10-03 2019-07-10 Philogen S.p.A. Antibody conjugate for use in treating inflammatory bowel disease
BR112016016658A2 (pt) * 2014-02-06 2018-01-23 F. Hoffmann-La Roche Ag proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
GB201507908D0 (en) 2015-05-08 2015-06-24 Philogen Spa IL2 and TNF immunoconjugates
AU2016293114A1 (en) 2015-07-16 2018-02-01 Philogen S.P.A. IL22 immunoconjugates
US20190309060A1 (en) 2016-01-15 2019-10-10 Philogen S.P.A. Intestinal antigens for pharmacodelivery applications
JP2017197558A (ja) * 2017-06-07 2017-11-02 フィロゲン エスピーエー 炎症性腸疾患に関連する抗原
AU2018281871B2 (en) 2017-06-07 2022-07-28 Philogen S.P.A. Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
CN116322785A (zh) 2020-07-20 2023-06-23 德卡生物科学公司 包含il-10的双细胞因子融合蛋白
EP4185615A1 (en) 2020-07-22 2023-05-31 Philogen S.p.A. Treatment of pulmonary hypertension
CN113480636B (zh) * 2021-06-23 2023-11-03 烟台科瑞斯生物技术有限责任公司 重组人纤连蛋白及其制备、活性测定和稳定性实验方法
WO2023175077A1 (en) 2022-03-17 2023-09-21 Philogen S.P.A Anti-ed-a antibodies for the treatment of pulmonary hypertension

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IT1217724B (it) 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
US5420012A (en) 1989-05-08 1995-05-30 Locus Genex Oy Method for the detection of reactive conditions
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
EP0580859A4 (en) * 1991-03-26 1994-09-14 Otsuka Pharma Co Ltd Anti-eda monoclonal antibody
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
US5644033A (en) 1992-12-22 1997-07-01 Health Research, Inc. Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
AU6098994A (en) 1993-01-27 1994-08-15 Duke University Methods and agents for the diagnosis and treatment of rheumatoid arthritis
US6054312A (en) * 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
EP2154535A1 (en) 1998-12-10 2010-02-17 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
AU2001239470A1 (en) 2000-02-24 2001-09-03 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
EP1275398A4 (en) * 2000-04-06 2004-09-01 Kyowa Hakko Kogyo Kk DIAGNOSTICS AND REMEDIES AGAINST RHUMATOID POLYARTHRITIS
WO2001083816A2 (en) 2000-05-04 2001-11-08 Philogen S.R.L. Method for detecting tumors
SK2882003A3 (en) 2000-09-07 2003-08-05 Schering Ag Receptor in the EDb fibronectin domain
US6780594B2 (en) 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
IT1317108B1 (it) 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
US20020187100A1 (en) 2000-12-21 2002-12-12 David Rizzieri Anti-tenascin monoclonal antibody therapy for lymphoma
EP1224943A1 (en) 2001-01-19 2002-07-24 Crucell Holland B.V. Fibronectin as a tumor marker detected by phage antibodies
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
AU2003238284A1 (en) 2002-06-21 2004-01-06 Duke University Anti-tenascin antibody fragments and minibodies for treatment of lymphoma
US7803372B2 (en) * 2002-10-08 2010-09-28 Immunomedics, Inc. Antibody therapy
AU2003288467A1 (en) 2002-12-13 2004-07-09 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
WO2004094612A2 (en) 2003-04-22 2004-11-04 A & G Pharmaceutical, Inc. Cancer specific monoclonal antibodies
WO2005009366A2 (en) 2003-07-24 2005-02-03 Cornell Research Foundation, Inc. Restoring vascular function
CA2533878A1 (en) 2003-07-29 2005-09-22 Immunomedics, Inc. Fluorinated carbohydrate conjugates
EA011859B9 (ru) 2004-01-05 2013-07-30 Емд Лексиген Ресерч Сентер Корп. Соединения для адресной доставки препарата к ткани или органу-мишени
US20060024757A1 (en) 2004-07-30 2006-02-02 Robert Hussa Detection of oncofetal fibronectin for selection of concepti
US7785591B2 (en) * 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
CA2586661A1 (en) 2004-11-09 2006-05-18 Philogen S.P.A. Antibodies against tenascin-c
CN101124243A (zh) * 2004-12-23 2008-02-13 莫尔梅德股份有限公司 缀合产物
CN101258162A (zh) * 2005-05-11 2008-09-03 菲罗根股份公司 抗纤连蛋白ed-b和白细胞介素12的抗体l19的融合蛋白
WO2007001940A2 (en) 2005-06-23 2007-01-04 Emory University Imaging agents
JP2009535372A (ja) 2006-05-03 2009-10-01 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 抗ｅｄｂフィブロネクチンドメイン抗体ｌ１９−ｓｉｐ及び抗−ｅｇｆｒ−抗体の組合せ
ES2606490T3 (es) 2006-05-08 2017-03-24 Philogen S.P.A. Citocinas dirigidas por anticuerpos para terapia
AU2008234615B2 (en) * 2007-04-02 2013-10-10 Philogen S.P.A. The ED-A antigen of fibrinogen is associated with the neovasculature of tumour metastases
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
US20100183506A1 (en) 2007-07-25 2010-07-22 Dario Neri Antigen associated with lung cancers and lymphomas
EP3783019A1 (en) 2007-10-30 2021-02-24 Philogen S.p.A. An antigen associated with rheumatoid arthritis
WO2010078950A2 (en) 2009-01-07 2010-07-15 Philogen S.P.A. Antigens associated with endometriosis, psoriatic arthritis and psoriasis
CA2748291A1 (en) 2009-01-07 2010-07-15 Philogen S.P.A. Cancer treatment
EP3842074A1 (en) 2010-09-29 2021-06-30 Philogen S.p.A. Protein-drug conjugates
CA2842053C (en) 2011-07-27 2018-01-16 Philogen S.P.A. Il-12 immunoconjugate
EP2903629B1 (en) 2012-10-03 2019-07-10 Philogen S.p.A. Antibody conjugate for use in treating inflammatory bowel disease
WO2014174105A1 (en) 2013-04-25 2014-10-30 Philochem Ag Antibody-drug conjugates
EP2988826A1 (en) 2013-04-26 2016-03-02 Philogen S.p.A. Il4 conjugated to antibodies against extracellular matrix components
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
KR20100101587A (ko) 2010-09-17
JP6198703B2 (ja) 2017-09-20
JP6154594B2 (ja) 2017-06-28
US20190352384A1 (en) 2019-11-21
US10385121B2 (en) 2019-08-20
EP3281952A1 (en) 2018-02-14
EP3783019A1 (en) 2021-02-24
CN103396483B (zh) 2016-11-23
PT3281952T (pt) 2020-07-23
JP5106635B2 (ja) 2012-12-26
US8222377B2 (en) 2012-07-17
CN101918443B (zh) 2013-07-17
ES2646228T3 (es) 2017-12-12
KR101608544B1 (ko) 2016-04-01
HUE037036T2 (hu) 2018-08-28
AU2008317941A1 (en) 2009-05-07
US9556257B2 (en) 2017-01-31
SI3281952T1 (sl) 2020-09-30
US20100260707A1 (en) 2010-10-14
PL2209805T3 (pl) 2018-01-31
JP2011502137A (ja) 2011-01-20
US20170298122A1 (en) 2017-10-19
DK2209805T3 (en) 2017-10-16
AU2008317941B2 (en) 2015-01-22
KR102002739B1 (ko) 2019-07-23
CA2704296C (en) 2017-08-22
JP2015091799A (ja) 2015-05-14
CN103396483A (zh) 2013-11-20
HUE050038T2 (hu) 2020-11-30
EP2209805A1 (en) 2010-07-28
PL3281952T3 (pl) 2020-11-16
NO2209805T3 (pt) 2018-02-03
WO2009056268A1 (en) 2009-05-07
CN101918443A (zh) 2010-12-15
KR20160039305A (ko) 2016-04-08
ES2807753T3 (es) 2021-02-24
SI2209805T1 (sl) 2017-11-30
JP2013040183A (ja) 2013-02-28
RU2010121874A (ru) 2011-12-10
BRPI0818272B8 (pt) 2021-05-25
BRPI0818272B1 (pt) 2021-01-12
DK3281952T3 (da) 2020-08-03
KR20180027640A (ko) 2018-03-14
US20120244114A1 (en) 2012-09-27
MX2010004726A (es) 2010-05-20
RU2649368C2 (ru) 2018-04-02
EP3281952B1 (en) 2020-06-24
KR101836968B1 (ko) 2018-03-12
RU2486198C2 (ru) 2013-06-27
PT2209805T (pt) 2017-11-14
RU2013115891A (ru) 2014-10-20
CA2704296A1 (en) 2009-05-07
EP2209805B1 (en) 2017-09-06

Similar Documents

Publication Publication Date Title
BRPI0818272A2 (pt) Antígeno associado com artrite reumatóide
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0809677A2 (pt) Anticorpos anti-ige
BRPI0715703A2 (pt) anticorpos anti-c5ar com propriedades melhoradas
BRPI0817427A2 (pt) Anticorpo anti-bst2
DK2132234T3 (da) Acceleratoropløsning
DK2129588T3 (da) Flaske
UA15924S (uk) Футляр до пляшки
TH110653B (th) P-แคดฮีรินแอนติบอดี
UA13879S (uk) Пляшка
UA15611S (uk) Пляшка
TH98660B (th) ขวด
TH95028B (th) ขวด
UA13880S (uk) Пляшка
UA13881S (uk) Пляшка
UA14143S (uk) Пляшка
UA14144S (uk) Пляшка
UA14164S (uk) Пляшка
UA14428S (uk) Пляшка
UA14447S (uk) Пляшка
UA14602S (uk) Флакон
UA14948S (uk) Пляшка
UA15131S (uk) Пляшка
UA15132S (uk) Пляшка
TH97254B (th) ขวด

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF